{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Anti-inflammation", "Antibody array", "Doxorubicin", "Melatonin", "Multidrug resistance", "p53", "qRT-PCR"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36651944", "DateCompleted": {"Year": "2023", "Month": "05", "Day": "17"}, "DateRevised": {"Year": "2023", "Month": "06", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "01", "Day": "18"}], "Language": ["eng"], "ELocationID": ["10.1007/s00210-023-02385-w"], "Journal": {"ISSN": "1432-1912", "JournalIssue": {"Volume": "396", "Issue": "6", "PubDate": {"Year": "2023", "Month": "Jun"}}, "Title": "Naunyn-Schmiedeberg's archives of pharmacology", "ISOAbbreviation": "Naunyn Schmiedebergs Arch Pharmacol"}, "ArticleTitle": "Anti-drug resistance, anti-inflammation, and anti-proliferation activities mediated by melatonin in doxorubicin-resistant hepatocellular carcinoma: in vitro investigations.", "Pagination": {"StartPage": "1117", "EndPage": "1128", "MedlinePgn": "1117-1128"}, "Abstract": {"AbstractText": ["Hepatocellular carcinoma (HCC) is the major life-threatening primary liver malignancy in both sexes all over the world. Unfortunately, the majority of patients are diagnosed at later stages because HCC does not elicit obvious symptoms during its early incidence. Consequently, most individuals escape the first-line HCC treatments and are treated with chemotherapy. Regrettably, the therapeutic outcomes for those patients are usually poor because of the development of multidrug resistance phenomena. Furthermore, most anti-HCC therapies cause severe undesired side effects that notably interfere with the life quality of such patients. Accordingly, there is an important need to search for an alternative therapeutic drug or adjuvant which is more efficient with safe or even minimal side effects for HCC treatment. Melatonin was recently reported to exert intrinsic antitumor activity in different cancers. However, the regulatory pathways underlying the antitumor activity of melatonin are poorly understood in resistant liver cells. Furthermore, a limited number of studies have addressed the therapeutic role of melatonin in HCC cells resistant to doxorubicin chemotherapy. In this study, we investigated the antitumor effects of melatonin in doxorubicin-resistant HepG2 cells and explored the regulatory pivotal targets underlying these effects. To achieve our aim, an MTT assay was used to calculate the 50% inhibitory concentration of melatonin and evaluate its antiproliferative effect on resistant cells. Additionally, qRT-PCR was used to quantify genes having a role in drug resistance phenotype (ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, and ABCG2); apoptosis (caspases-3, and -7, Bcl2, Bax, and p53); anti-oxidation (NRF2); expression of melatonin receptors (MT1, MT2, and MT3); besides, programmed death receptor PD-1 gene. The active form of the caspase-3 enzyme was estimated by ELISA. A human inflammatory antibody membrane array was employed to quantify forty inflammatory factors expressed in treated cells. We observed that melatonin inhibited the proliferation of doxorubicin-resistant HepG2 cells in a dose-dependent manner after 24-h incubation time with a calculated IC<sub>50</sub> greater than 10\u00a0mM (13.4\u00a0mM), the expression levels of genes involved in drug resistance response (ABCB1, ABCC1, ABCC5, and ABCG2) were downregulated. Also, the expression of caspase-3, Caspase-7, NRF2, and p53 genes were expressed at higher levels as compared to control (DMSO-treated cells). An active form of caspase-3 was confirmed by ELISA. Moreover, the anti-inflammatory effect of melatonin was detected through the calculated fold change to control which was reduced for various mediators that have a role in the inflammation pathway. The current findings introduce melatonin as a promising anti-cancer treatment for human-resistant HCC which could be used in combination with current chemotherapeutic regimens to improve the outcome and reduce the developed multidrug resistance."], "CopyrightInformation": "\u00a9 2023. The Author(s)."}, "AuthorList": [{"Identifier": ["0000-0003-2691-7725"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry of Medicinal Plants Department, and Biology Unit, Central Laboratory for Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El-Bohouth St, Dokki, Giza, 12622, Egypt."}], "LastName": "Hamed", "ForeName": "Ahmed R", "Initials": "AR"}, {"Identifier": ["0000-0003-1526-9603"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hormones Department, Medicine and Clinical Studies Research Institute, and Stem Cell Lab, Centre of Excellence for Advanced Sciences, National Research Centre, 33 El-Bohouth St, Dokki, Giza, 12622, Egypt."}], "LastName": "Yahya", "ForeName": "Shaymaa M M", "Initials": "SMM"}, {"Identifier": ["0000-0002-4660-8404"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical Biochemistry Department, Medicine and Clinical Studies Research Institute, National Research Centre, 33 El-Bohouth St, Dokki, Giza, 12622, Egypt. hk.nabih@nrc.sci.eg."}], "LastName": "Nabih", "ForeName": "Heba K", "Initials": "HK"}], "GrantList": [{"GrantID": "12060125", "Agency": "National Research Centre", "Country": ""}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Naunyn Schmiedebergs Arch Pharmacol", "NlmUniqueID": "0326264", "ISSNLinking": "0028-1298"}, "ChemicalList": [{"RegistryNumber": "JL5DK93RCL", "NameOfSubstance": "Melatonin"}, {"RegistryNumber": "EC 3.4.22.-", "NameOfSubstance": "Caspase 3"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-E2-Related Factor 2"}, {"RegistryNumber": "80168379AG", "NameOfSubstance": "Doxorubicin"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pathology"], "DescriptorName": "Carcinoma, Hepatocellular"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Melatonin"}, {"QualifierName": [], "DescriptorName": "Caspase 3"}, {"QualifierName": ["pathology"], "DescriptorName": "Liver Neoplasms"}, {"QualifierName": [], "DescriptorName": "NF-E2-Related Factor 2"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Doxorubicin"}, {"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Drug Resistance, Neoplasm"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ammar OA, El-Missiry MA, Othman AI, Amer ME. Melatonin is a potential oncostatic agent to inhibit HepG2 cell proliferation through multiple pathways. Heliyon. 2022;8(1):e08837. doi: 10.1016/j.heliyon.2022.e08837.", "ArticleIdList": ["10.1016/j.heliyon.2022.e08837", "PMC8814902", "35141433"]}, {"Citation": "Ao L, Li L, Sun H, Chen H, Li Y, Huang H, Wang X, Guo Z, Zhou R. Transcriptomic analysis on the effects of melatonin in gastrointestinal carcinomas. BMC Gastroenterol. 2020;20:233. doi: 10.1186/s12876-020-01383-z.", "ArticleIdList": ["10.1186/s12876-020-01383-z", "PMC7372748", "32689938"]}, {"Citation": "Bekyarova G, Tzaneva M. Melatonin ameliorates burn-induced liver injury by modulation of Nrf2 and Nf- kB signaling pathways. SOJ Immunol. 2015;3(2):1\u20138. doi: 10.15226/soji/3/3/00128.", "ArticleIdList": ["10.15226/soji/3/3/00128"]}, {"Citation": "Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Saut\u00e8s-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell\u2013dependent mechanism. Blood. 2002;99(6):2114\u20132121. doi: 10.1182/blood.V99.6.2114.", "ArticleIdList": ["10.1182/blood.V99.6.2114", "11877287"]}, {"Citation": "Bennukul K, Numkliang S, Leardkamolkarn V. Melatonin attenuates cisplatin-induced HepG2 cell death via the regulation of mTOR and ERCC1 expressions. World J Hepatol. 2014;6(4):230\u2013242. doi: 10.4254/wjh.v6.i4.230.", "ArticleIdList": ["10.4254/wjh.v6.i4.230", "PMC4009479", "24799992"]}, {"Citation": "Bu L-J, Yu H-Q, Fan L-L, Li X-Q, Wang F, Liu J-T, Wang H. Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation. World J Gastroenterol. 2017;23(6):986. doi: 10.3748/wjg.v23.i6.986.", "ArticleIdList": ["10.3748/wjg.v23.i6.986", "PMC5311108", "28246472"]}, {"Citation": "Carbajo-Pescador S, Ordonez R, Benet M, Jover R, Garcia-Palomo A, Mauriz J, Gonzalez-Gallego J. Inhibition of VEGF expression through blockade of Hif1i and STAT3 signalling mediates the antiangiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013;109(1):83\u201391. doi: 10.1038/bjc.2013.285.", "ArticleIdList": ["10.1038/bjc.2013.285", "PMC3708553", "23756865"]}, {"Citation": "Chen Y, Zhang J, Zhao Q, Chen Q, Sun Y, Jin Y, Wu J. Melatonin induces anti-inflammatory effects to play a protective role via endoplasmic reticulum stress in acute pancreatitis. Cell Physiol Biochem. 2016;40:1094\u20131104. doi: 10.1159/000453164.", "ArticleIdList": ["10.1159/000453164", "27960163"]}, {"Citation": "Chuffa LG, Alves MS, Martinez M, Camargo IC, Pinheiro PF, Domeniconi RF, J\u00fanior LA, Francisco Martinez E. Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma. Soc Endocrinol. 2016;23(2):65\u201376.", "ArticleIdList": ["26555801"]}, {"Citation": "Colares JR, Hartmann RM, Schemitt EG, Fonseca SRB, Brasil MS, Picada JN, Dias AS, Bueno AF, Marroni CA, Marroni NP. Melatonin prevents oxidative stress, inflammatory activity, and DNA damage in cirrhotic rats. World J Gastroenterol. 2022;28(3):348\u2013364. doi: 10.3748/wjg.v28.i3.348.", "ArticleIdList": ["10.3748/wjg.v28.i3.348", "PMC8771613", "35110954"]}, {"Citation": "Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol. 2016;3(1):57\u201359. doi: 10.2217/hep.15.41.", "ArticleIdList": ["10.2217/hep.15.41", "PMC4792121", "26998221"]}, {"Citation": "Das NK, Samanta S. The potential anti-cancer effects of melatonin on breast cancer. Explor Med. 2022;3:112\u2013127. doi: 10.37349/emed.2022.00078.", "ArticleIdList": ["10.37349/emed.2022.00078"]}, {"Citation": "Duan B, Huang C, Bai J, Zhang YL, Wang X, Yang J, Li J (2019) Multidrug resistance in hepatocellular carcinoma. In: Tirnitz-Parker JEE, (ed). Hepatocellular carcinoma [Internet]. Brisbane (AU): Codon Publications. Chapter 8. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549189/. 10.15586/hepatocellularcarcinoma.2019.ch8", "ArticleIdList": ["31664799"]}, {"Citation": "Fan L-L, Sun G-P, Wei W, Wang Z-G, Ge L, Fu W-Z, Wang H. Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol: WJG. 2010;16(12):1473. doi: 10.3748/wjg.v16.i12.1473.", "ArticleIdList": ["10.3748/wjg.v16.i12.1473", "PMC2846252", "20333787"]}, {"Citation": "Fan L, Sun G, Ma T, Zhong F, Lei Y, Li X, Wei W. Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing Survivin. J Pineal Res. 2013;55(2):184\u2013194. doi: 10.1111/jpi.12061.", "ArticleIdList": ["10.1111/jpi.12061", "23711089"]}, {"Citation": "Favero G, Franceschetti L, Bonomini F, Rodella LF, Rezzani R (2017) Melatonin as an anti-Inflammatory agent modulating inflammasome activation. Int J Endocrinol 2017:1835195. 10.1155/2017/1835195", "ArticleIdList": ["PMC5643098", "29104591"]}, {"Citation": "Fern\u00e1ndez-Palanca P, M\u00e9ndez-Blanco C, Fondevila F, Tu\u00f1\u00f3n MJ, Reiter RJ, Mauriz JL, Gonz\u00e1lez-Gallego J. Melatonin as an antitumor agent against liver cancer: an updated systematic review. Antioxidants. 2021;10(1):103. doi: 10.3390/antiox10010103.", "ArticleIdList": ["10.3390/antiox10010103", "PMC7828223", "33445767"]}, {"Citation": "Giraud J, Chalopin D, Blanc J-F, Saleh M. Hepatocellular carcinoma immune landscape and the potential of immunotherapies. Front. Immunol. 2021;12:655697. doi: 10.3389/fimmu.2021.655697.", "ArticleIdList": ["10.3389/fimmu.2021.655697", "PMC8012774", "33815418"]}, {"Citation": "Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med. 2009;11:e5. doi: 10.1017/S1462399409000982.", "ArticleIdList": ["10.1017/S1462399409000982", "PMC4301735", "19193248"]}, {"Citation": "Gurunathan S, Qasim M, Kang M-H, Kim J-H. Role and therapeutic potential of melatonin in various type of cancers. Onco Targets Ther. 2021;14:2019\u20132052. doi: 10.2147/OTT.S298512.", "ArticleIdList": ["10.2147/OTT.S298512", "PMC7987311", "33776451"]}, {"Citation": "Hac\u0131\u015fevki A, Baba B (2018) An overview of melatonin as an antioxidant molecule: a biochemical approach. In: Dr\u0103goi CM, Nicolae AC (eds) Melatonin - molecular biology, clinical and pharmaceutical approaches [Internet]. London: IntechOpen. Available from: https://www.intechopen.com/chapters/62672"}, {"Citation": "Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72:1125\u20131151. doi: 10.1007/s43440-020-00138-7.", "ArticleIdList": ["10.1007/s43440-020-00138-7", "32700248"]}, {"Citation": "Hamed AR, Emara M, Soltan MM, Yahya SM, Nabih HK, Elsayed GH. Investigating the role of miRNA-98 and miRNA-214 in chemoresistance of HepG2/Dox cells: studying their effects on predicted ABC transporters targets. Med Chem Res. 2018;27:531\u2013537. doi: 10.1007/s00044-017-2079-3.", "ArticleIdList": ["10.1007/s00044-017-2079-3"]}, {"Citation": "Hao J, Li Z, Zhang C, Yu W, Tang Z, Li Y, Huang W. Targeting NF-\u03baB/AP-2\u03b2 signaling to enhance antitumor activity of cisplatin by melatonin in hepatocellular carcinoma cells. Am J Cancer Res. 2017;7(1):13.", "ArticleIdList": ["PMC5250677", "28123844"]}, {"Citation": "Hermyt E, Zmarz\u0142y N, Grabarek B, Kruszniewska-Rajs C, Gola J, J\u0119da-Golonka A, Szczepanek K, Mazurek U, Witek A. Interplay between miRNAs and genes associated with cell proliferation in endometrial cancer. Int J Mol Sci. 2019;20:6011. doi: 10.3390/ijms20236011.", "ArticleIdList": ["10.3390/ijms20236011", "PMC6928856", "31795319"]}, {"Citation": "Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets. 2006;6(4):295\u2013311. doi: 10.2174/156800906777441753.", "ArticleIdList": ["10.2174/156800906777441753", "16848721"]}, {"Citation": "Hou C, Lu L, Liu Z, Lian Y, Xiao J. Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3/VEGF pathway. FEBS Open Bio. 2021;11:2256\u20132265. doi: 10.1002/2211-5463.13230.", "ArticleIdList": ["10.1002/2211-5463.13230", "PMC8329954", "34129726"]}, {"Citation": "Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: An Overview. Cancers. 2014;6(3):1769\u20131792. doi: 10.3390/cancers6031769.", "ArticleIdList": ["10.3390/cancers6031769", "PMC4190567", "25198391"]}, {"Citation": "Hsieh M-J, Lin C-W, Su S-C, Reiter RJ, Chen AW, Chen M-K, Yang S-F. Effects of miR-34b/miR-892a Upregulation and Inhibition of ABCB1/ABCB4 on Melatonin-Induced Apoptosis in VCR-Resistant Oral Cancer Cells. Mol Ther - Nucleic Acids. 2020;19:877\u2013889. doi: 10.1016/j.omtn.2019.12.022.", "ArticleIdList": ["10.1016/j.omtn.2019.12.022", "PMC6994412", "31982774"]}, {"Citation": "Javier M-R, Mauriz J-L, Jorquera F, Olga R-A, Gonzalez P, Gonz\u00e1lez-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res. 2008;45:532\u2013540. doi: 10.1111/j.1600-079x.2008.00641.x.", "ArticleIdList": ["10.1111/j.1600-079x.2008.00641.x", "19012662"]}, {"Citation": "Kang SH, Chess-Williams R, Anoopkumar-Dukie S, McDermott C. Induction ofinflammatory cytokines and alteration of urothelial ATP, acetylcholine and prostaglandin E2 releaseby doxorubicin. Eur J Pharmacol. 2013;700(1\u20133):102\u2013109. doi: 10.1016/j.ejphar.2012.11.053.", "ArticleIdList": ["10.1016/j.ejphar.2012.11.053", "23219793"]}, {"Citation": "Kim SD, Baik JS, Lee J-H, Mun S-W, Yi JM, Park M-T. The malignancy of liver cancer cells is increased by IL-4/ERK/AKT signaling axis activity triggered by irradiated endothelial cells. J Radiat Res. 2020;61(3):376\u2013387. doi: 10.1093/jrr/rraa002.", "ArticleIdList": ["10.1093/jrr/rraa002", "PMC7299255", "32100006"]}, {"Citation": "Lauko A, Bayik D, Lathia JD. IL-11 drives postsurgical hepatocellular carcinoma recurrence. EBioMedicine. 2019;47:18\u201319. doi: 10.1016/j.ebiom.2019.08.007.", "ArticleIdList": ["10.1016/j.ebiom.2019.08.007", "PMC6796539", "31402232"]}, {"Citation": "Liu K, Song J, Yan Y, Zou K, Che Y, Wang B, Li Z, Yu W, Guo W, Zou L, Deng W, Sun X. Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-\u03baB pathway. Translational Oncology. 2021;14(1):100876. doi: 10.1016/j.tranon.2020.100876.", "ArticleIdList": ["10.1016/j.tranon.2020.100876", "PMC7527585", "33007707"]}, {"Citation": "Lotfi R, Lee JJ, Lotze MTJ. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother. 2007;30:16\u201328. doi: 10.1097/01.cji.0000211324.53396.f6.", "ArticleIdList": ["10.1097/01.cji.0000211324.53396.f6", "17198080"]}, {"Citation": "Lu C-S, Shiau A-L, Su B-H, Hsu T-S, Wang C-T, Su Y-C, Tsai M-S, Feng Y-H, Tseng Y-L, Yen Y-T, Wu C-L, Shieh G-S. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer. J Hematol Oncol. 2020;13(1):62. doi: 10.1186/s13045-020-00887-1.", "ArticleIdList": ["10.1186/s13045-020-00887-1", "PMC7268452", "32487125"]}, {"Citation": "Mart\u00edn V, Sanchez-Sanchez A, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antol\u00edn I, Rodriguez C. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 2013;108:2005\u20132012. doi: 10.1038/bjc.2013.188.", "ArticleIdList": ["10.1038/bjc.2013.188", "PMC3670480", "23632480"]}, {"Citation": "Mart\u00ednez-Campa C, Men\u00e9ndez-Men\u00e9ndez J, Alonso-Gonz\u00e1lez C, Gonz\u00e1lez A, Gonz\u00e1lez-Gonz\u00e1lez A, Cos S (2017) Signalling Pathways Targeted by Melatonin in Cancer. A Short Review. J Tumor Med Prev 1(4): JTMP.MS.ID.555570"}, {"Citation": "Mehrzadi S, Pourhanifeh MH, Mirzaei A, Moradian F, Hosseinzadeh A. An updated review of mechanistic potentials of melatonin against cancer: pivotal roles in angiogenesis, apoptosis, autophagy, endoplasmic reticulum stress and oxidative stress. Cancer Cell Int. 2021;21:188. doi: 10.1186/s12935-021-01892-1.", "ArticleIdList": ["10.1186/s12935-021-01892-1", "PMC8011077", "33789681"]}, {"Citation": "Moreira AJ, Ordo\u00f1ez R, Cerski CT, Picada JN, Garc\u00eda-Palomo A, Marroni NP, Mauriz JL, Gonz\u00e1lez-Gallego J. Melatonin activates endoplasmic reticulum stress and apoptosis in rats with diethylnitrosamine-induced hepatocarcinogenesis. PLoS ONE. 2015;10(12):e0144517. doi: 10.1371/journal.pone.0144517.", "ArticleIdList": ["10.1371/journal.pone.0144517", "PMC4684373", "26656265"]}, {"Citation": "Mortezaee K. Human hepatocellular carcinoma: protection by melatonin. J Cell Physiol. 2018;233:6486\u20136508. doi: 10.1002/jcp.26586.", "ArticleIdList": ["10.1002/jcp.26586", "29672851"]}, {"Citation": "N\u00fa\u00f1ez-Iglesias MJ, Novio S, Garc\u00eda-Santiago C, Cartea ME, Soengas P, Velasco P, Freire-Garabal M. Effects of 3-butenyl isothiocyanate on phenotypically different prostate cancer cells. Int J Oncol. 2018;53:2213\u20132223.", "ArticleIdList": ["30226593"]}, {"Citation": "Ordo\u00f1ez R, Fern\u00e1ndez A, Prieto-Dom\u00ednguez N, Mart\u00ednez L, Garc\u00eda-Ruiz C, Fern\u00e1ndez-Checa JC, Mauriz JL, Gonz\u00e1lez-Gallego J. Ceramide metabolism regulates autophagy and apoptotic cell death induced by melatonin in liver cancer cells. J Pineal Res. 2015;59:178\u2013189. doi: 10.1111/jpi.12249.", "ArticleIdList": ["10.1111/jpi.12249", "PMC4523438", "25975536"]}, {"Citation": "Pahlavani N, Kiapey SM, Firouzi S, Malekahmadi M. Role of melatonin supplementation on inflammatory and oxidative stress markers in critically Ill patients. Int J Med Rev. 2018;5(4):143\u2013145. doi: 10.29252/IJMR-050403.", "ArticleIdList": ["10.29252/IJMR-050403"]}, {"Citation": "Schettig R, Sears T, Klein M, Tan-Lim R, Matthias R, Aussems C, Hummel M, Sears R, Poteet Z, Warren D, Oertle J, Coffin C, Prato D. Melatonin: a powerful integrative adjunctive agent for oncology. J Cancer Ther. 2020;11:571\u2013596. doi: 10.4236/jct.2020.119049.", "ArticleIdList": ["10.4236/jct.2020.119049"]}, {"Citation": "Song N, Kim AJ, Kim HJ, Jee HJ, Kim M, Yoo YH, Yun J. Melatonin suppresses doxorubicin-induced premature senescence of A549 lung cancer cells by ameliorating mitochondrial dysfunction. J Pineal Res. 2012;53(4):335\u2013343. doi: 10.1111/j.1600-079X.2012.01003.x.", "ArticleIdList": ["10.1111/j.1600-079X.2012.01003.x", "22536785"]}, {"Citation": "St. John MA. Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma. Laryngoscope. 2015;125:S1\u2013S11. doi: 10.1002/lary.24998.", "ArticleIdList": ["10.1002/lary.24998", "25646683"]}, {"Citation": "Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter RJ, Yang SF. Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res. 2017;62(1):e12370. doi: 10.1111/jpi.12370.", "ArticleIdList": ["10.1111/jpi.12370", "27706852"]}, {"Citation": "Sun Y, Wu H, Chen G, Huang X, Shan Y, Shi H, Zhang Q, Zheng Y. Genetically engineered recombinant adenovirus expressing interleukin-2 for hepatocellular carcinoma therapy. Mol Med Rep. 2018;17:300\u2013306.", "ArticleIdList": ["29115604"]}, {"Citation": "Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI. Melatonin in cancer treatment: current knowledge and future opportunities. Molecules. 2021;26:2506. doi: 10.3390/molecules26092506.", "ArticleIdList": ["10.3390/molecules26092506", "PMC8123278", "33923028"]}, {"Citation": "Tano\u011flu GE, Tano\u011flu A, Aydin MCM, Esen MF. Melatonin has favorable preventive effects on experimental chronic pancreatitis rat model. Turk J Med Sci. 2021;51:2734\u20132740. doi: 10.3906/sag-2103-134.", "ArticleIdList": ["10.3906/sag-2103-134", "PMC8742498", "34247466"]}, {"Citation": "Teng D, Ding L, Cai B, Luo Q, Wang H. Interleukin-7 enhances anti-tumor activity of CD8 + T cells in patients with hepatocellular carcinoma. Cytokine. 2018;118:115\u2013123. doi: 10.1016/j.cyto.2018.04.003.", "ArticleIdList": ["10.1016/j.cyto.2018.04.003", "29655570"]}, {"Citation": "Vyas D, Laput G, Vyas A. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther. 2014;7:1015\u20131023. doi: 10.2147/OTT.S60114.", "ArticleIdList": ["10.2147/OTT.S60114", "PMC4061164", "24959088"]}, {"Citation": "Wang Q, Shu C, Su J, Li X. A crosstalk triggered by hypoxia and maintained by MCP-1/miR-98/IL-6/p38 regulatory loop between human aortic smooth muscle cells and macrophages leads to aortic smooth muscle cells apoptosis via Stat1 activation. Int J Clin Exp Pathol. 2015;8:2670\u20132679.", "ArticleIdList": ["PMC4440081", "26045772"]}, {"Citation": "Wang D-Y, Zou L-P, Liu X-J, Zhu H-G, Zhu R. chemokine expression profiles of human hepatoma cell lines mediated by hepatitis B virus X protein. Pathol Oncol Res. 2016;22:393\u2013399. doi: 10.1007/s12253-015-0014-9.", "ArticleIdList": ["10.1007/s12253-015-0014-9", "26581611"]}, {"Citation": "Wang L, Chen Q, Qi H, Wang C, Wang C, Zhang J, Dong L. Doxorubicin-induced systemic inflammation is driven by upregulation of toll-like receptor TLR4 and endotoxin leakage. Cancer Res. 2016;76(22):6631\u20136642. doi: 10.1158/0008-5472.CAN-15-3034.", "ArticleIdList": ["10.1158/0008-5472.CAN-15-3034", "27680684"]}, {"Citation": "Wang T-H, Wu C-H, Yeh C-T, Su S-C, Hsia S-M, Liang K-H, Chen C-C, Hsueh C, Chen C-Y. Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1\u03b1 inactivation. Oncotarget. 2017;8:82280\u201382293. doi: 10.18632/oncotarget.19316.", "ArticleIdList": ["10.18632/oncotarget.19316", "PMC5669889", "29137263"]}, {"Citation": "Wang T-H, Hsueh C, Chen C-C, Li W-S, Yeh C-T, Lian J-H, Chang J-L, Chen C-Y. Melatonin inhibits the progression of hepatocellular carcinoma through microRNA Let7i-3p mediated RAF1 reduction. Int J Mol Sci. 2018;19(9):2687. doi: 10.3390/ijms19092687.", "ArticleIdList": ["10.3390/ijms19092687", "PMC6163650", "30201903"]}, {"Citation": "Wongsena W, Charoensuk L, Dangtakot R, Pinlaor P, Intuyod K, Pinlaor S. Melatonin suppresses eosinophils and Th17 cells in hamsters treated with a combination of human liver fluke infection and a chemical carcinogen. Pharmacol Rep. 2018;70:98\u2013105. doi: 10.1016/j.pharep.2017.07.017.", "ArticleIdList": ["10.1016/j.pharep.2017.07.017", "29331794"]}, {"Citation": "Yahya SM, Hamed AR, Emara M, Soltan MM, Abd-Ellatef GE, Abdelnasser SM. Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells. Tumour Biol. 2016;37(5):5925\u20135932. doi: 10.1007/s13277-015-4426-7.", "ArticleIdList": ["10.1007/s13277-015-4426-7", "26596829"]}, {"Citation": "Zare Javid A, Hosseini SA, Gholinezhad H, Moradi L, Haghighi-zadeh MH, Bazyar H. Antioxidant and anti-inflammatory properties of melatonin in patients with type 2 diabetes mellitus with periodontal disease under non-surgical periodontal therapy: a double-blind, placebo-controlled trial. Diabetes Metab Syndr Obes: Targets Ther. 2020;13:753\u2013761. doi: 10.2147/DMSO.S242208.", "ArticleIdList": ["10.2147/DMSO.S242208", "PMC7090208", "32256092"]}, {"Citation": "Zha L, Fan L, Sun G, Wang H, Ma T, Zhong F, Wei W. Melatonin sensitizes human hepatoma cells to endoplasmic reticulum stress-induced apoptosis. J Pineal Res. 2012;52(3):322\u2013331. doi: 10.1111/j.1600-079X.2011.00946.x.", "ArticleIdList": ["10.1111/j.1600-079X.2011.00946.x", "22225575"]}, {"Citation": "Zhelev Z, Ivanova D, Bakalova R, Aoki I, Higashi T. Synergistic cytotoxicity of melatonin and new-generation anticancer drugs against leukemia lymphocytes but not normal lymphocytes. Anticancer Res. 2017;37:149\u2013160. doi: 10.21873/anticanres.11300.", "ArticleIdList": ["10.21873/anticanres.11300", "28011485"]}, {"Citation": "Zheng H, Yang Y, Han J, Jiang W-H, Chen C, Wang M-C, Gao R, Li S, Tian T, Wang J, Ma L-J, Ren H, Zhou W-P. TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. Sci Rep. 2016;6:37070. doi: 10.1038/srep37070.", "ArticleIdList": ["10.1038/srep37070", "PMC5128793", "27901021"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "6", "Day": "16"}, {"Year": "2023", "Month": "1", "Day": "2"}, {"Year": "2023", "Month": "5", "Day": "17", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "1", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "18", "Hour": "11", "Minute": "14"}, {"Year": "2023", "Month": "1", "Day": "18"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36651944", "PMC10185645", "10.1007/s00210-023-02385-w", "10.1007/s00210-023-02385-w"]}}], "PubmedBookArticle": []}